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Abstract
Prion diseases are fatal neurodegenerative diseases, which can be acquired, sporadic or genetic, the latter being linked to
mutations in the gene encoding prion protein. We have recently described the importance of subdomain separation in the
conversion of prion protein (PrP). The goal of the present study was to investigate the effect of increasing the hydrophobic
interactions within the H2-H3 subdomain on PrP conversion. Three hydrophobic mutations were introduced into PrP. The
mutation V209I associated with human prion disease did not alter protein stability or in vitro fibrillization propensity of PrP.
The designed mutations V175I and T187I on the other hand increased protein thermal stability. V175I mutant fibrillized
faster than wild-type PrP. Conversion delay of T187I was slightly longer, but fluorescence intensity of amyloid specific dye
thioflavin T was significantly higher. Surprisingly, cells expressing V209I variant exhibited inefficient proteinase K resistant
PrP formation upon infection with 22L strain, which is in contrast to cell lines expressing wild-type, V175I and T187I mPrPs.
In agreement with increased ThT fluorescence at the plateau T187I expressing cell lines accumulated an increased amount
of the proteinase K-resistant prion protein. We showed that T187I induces formation of thin fibrils, which are absent from
other samples. We propose that larger solvent accessibility of I187 in comparison to wild-type and other mutants may
interfere with lateral annealing of filaments and may be the underlying reason for increased conversion efficiency.
Citation: Hafner-Bratkovic ˇ I, Gaedtke L, Ondracka A, Veranic ˇ P, Vorberg I, et al. (2011) Effect of Hydrophobic Mutations in the H2-H3 Subdomain of Prion Protein
on Stability and Conversion In Vitro and In Vivo. PLoS ONE 6(9): e24238. doi:10.1371/journal.pone.0024238
Editor: Jason Bartz, Creighton University, United States of America
Received June 17, 2011; Accepted August 3, 2011; Published September 1, 2011
Copyright:  2011 Hafner-Bratkovic ˇ et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors acknowledge the financial support from the state budget by the Slovenian Research Agency (IHB, RJ), EN-FIST Centre of Excellence (RJ),
DFG 1277/1-3 (IV), the 6th framework EU project, TSEUR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: roman.jerala@ki.si
. These authors contributed equally to this work.
¤ Current address: The Rockefeller University, New York, New York, United States of America
Introduction
Prion diseases are neurodegenerative diseases characterized by
misfolding of prion protein leading to pathologic amyloid deposits
in brains of humans and other mammals. Cellular prion protein is
composed of an N-terminal unstructured part and a globular C-
terminal domain, composed of three a-helices (H1, H2, H3) and
an antiparallel two-stranded b-sheet (B1, B2). This protein fold,
which is conserved in all vertebrate prion proteins with determined
structure, is stabilized by a tightly packed hydrophobic core, salt
bridges and hydrogen bonds [1]. During the course of the disease,
cellular prion protein (PrPC) undergoes conformational conver-
sion into its pathological aggregated form, PrPSc. In humans,
prion diseases can be sporadic, acquired or genetic, linked to
mutations in the gene encoding prion protein, PRNP. In the
globular domain over 20 different mutations in PRNP have been
associated with familial forms of prion disease, familial Creutz-
feldt-Jakob disease (fCJD), Gerstmann-Stra ¨ussler-Scheinker syn-
drome (GSS), and fatal familial insomnia (FFI) [2]. Some of these
mutations are in the hydrophobic core and about one third of the
mutations are substitutions for an amino acid with increased
hydrophobicity. Several mechanisms have been proposed to
explain how certain point mutations might modulate protein
misfolding, such as decreased thermodynamic stability of PrP
C
[3,4], increased stability of the folding intermediate (for V210I) [5]
or differences in posttranslational modifications and cellular
trafficking such as atypical glycosylation of V180I and T183A
[6,7]. The mechanism of PrP
C to PrP
Sc structural conversion is to
a large extent still unknown; particularly since the high resolution
structure of PrP
Sc could not be resolved. Nevertheless, based on
biochemical and biophysical characterization of PrP
Sc aggregates
and in vitro prepared PrP fibrils, several structural models of PrP
Sc
were proposed [8,9,10,11]. We recently demonstrated, using
disulfide tethering, that the hydrophobic core of the structured C-
terminal domain is affected since the subdomains B1-H1-B2 and
H2-H3 must separate during PrP conversion [11,12]. However,
disulfide tethers within subdomains did not prevent conversion,
suggesting domain swapping as the process underlying PrP
conversion [11].
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enhancement of the hydrophobic core of the H2-H3 globular
subdomain on the PrP fibrillization capacity and its conversion
into proteinase K resistant PrP (PrPres). Appropriately selected
hydrophobic mutants could increase the stability of the globular
domain or its subdomains and we wanted to investigate if
increasing the hydrophobicity had any effect on the fibrillization
propensities of these types of PrP mutants. Furthermore, cell
culture experiment was performed to reveal if PrP mutants could
form PrPres and support infection. Three hydrophobic mPrP
(mouse prion protein) mutants were selected, prepared and
correctly refolded. One of these mutants, T187I, demonstrated
increased formation of thin PrP fibrils in vitro and in cell culture
increased proteinase K-resistant PrP formation upon 22L prion
strain infection despite its increased stability. This mutant might
prove as a valuable substrate for in vitro seeding assays [13] and
scrapie cell assays [14].
Results
Selection of sites for introduction of hydrophobic
residues and their influence on thermal stability of mPrP
Several amino-acid substitutions increasing side chain hydro-
phobicity (e.g. V210I, T180A, T183A) lead to spontaneous prion
disease in humans. In this study we focused on the subdomain H2-
H3, which is tethered by the native disulfide bridge and where
many human pathogenic mutations reside. In addition to the
V209I mutant, which corresponds to the fCJD-causing mutation
V210I in humans, we selected two residues within the same
subdomain of PrP for mutagenesis. According to the determined
mPrP structures [15,16] side-chains of residues V175 and T187
residing in H2 are oriented toward H3 (Figure 1A). Amino-acid
residues V175, T187 and V209 are conserved among different
mammalian prion proteins. Substitution of residues V175 or T187
for a more hydrophobic isoleucine should increase the hydropho-
bic interactions between H2 and H3. There are no known
pathogenic mutations of V176 (corresponding to V175 in mPrP),
whereas very rare mutations of T188 to alanine, lysine or arginine
(corresponding to T187 in mPrP) were linked to hereditary prion
disease in humans [17]. In the mPrP structure V209 in H3 points
towards the interface of B2 (beta strand 2) and H3 and takes part
in the hydrophobic core, thus contributing to stabilization of the
overall fold. Since the side chains of V175I and T187I are limited
to the subdomain H2-H3 and do not interact with the other
subdomain, we anticipated differences in the effect of different
hydrophobic mutations on conversion.
In vitro studies of recombinant prion protein provided informa-
tion on the structure and stability of PrP
C [1] and insights into the
mechanism of PrP conversion [8,11,18]. Moreover, in vitro
converted bacterially expressed prion protein was shown to be
infectious to wild-type animals [19,20,21] conclusively proving
relevance of the in vitro conversion system. We therefore compared
biophysical properties and fibrillization propensities of recombi-
nant mPrP harboring single point mutations V175I, T187I and
V209I to wild-type mPrP. mPrPs carrying selected mutations were
expressed in form of inclusion bodies in bacteria and successfully
refolded. Characteristic minima at 208 nm and 222 nm in far-UV
CD spectra demonstrated that wild-type protein and all three
mutants had predominantly alpha-helical structure (Figure 1B)
indicating that mutations did not disrupt the protein fold. We were
further interested whether the introduced hydrophobic mutations
influenced the thermal stability of the protein. V209I mutant did
not have any influence on protein stability, as has been observed
previously [4]. In contrast thermal stability of T187I and V175I
was increased in comparison to both the wild-type and V209I
mPrP (Figure 1C, Table 1).
Hydrophobic mutants display different conversion
properties in vitro
In vitro fibrillization of hydrophobic mPrP mutants was
monitored by an increase of fluorescence of an amyloid specific
dye, thioflavin T (ThT) [22]. All prepared hydrophobic mutants
converted into the amyloid form (Figure 2A). In the time course of
conversion V175I slightly preceded fibril formation by wild-type
mPrP and V209I whereas mPrP T187I displayed an increase in
lag phase (Figure 2A). Negatively stained fibrils were present in
samples of all mPrP variants as observed under the transmission
electron microscope (Figure 2B). As in our previous study [11] we
concluded that there is no simple correlation between the stability
of PrP and lag phase in the fibrillization assay. V175I and T187I
were both more stable than wild-type, yet they reproducibly
fibrillized with either shorter or longer delay than the wild-type
mPrP, respectively. Surprisingly, the T187I mutant, which had the
longest fibrillization lag phase, exhibited significantly higher ThT
fluorescence intensity than other mPrPs (P,0.0005) (Figure 2C).
Although ThT is the most commonly used dye for detection of
amyloids, its mechanism of binding has not been resolved [23].
The amount of proteinase K-resistant prion protein was not
significantly different between wild-type and T187I samples (not
shown). Higher ThT fluorescence intensity could thus originate
from different types of amyloid structures formed as previously
observed [24,25].
Presence of thin fibrils in T187I fibrillization reactions
We wanted to explore the cause of differences in conversion of
PrP hydrophobic mutants. End-point fibrillization reactions (when
ThT fluorescence intensity reached maximum) were therefore
observed by atomic force microscopy. Diverse fibrillar structures
(e.g. branched, twisted amyloid fibrils) were observed in the
samples of wild-type, V175I and V209I mPrPs (Figure 3, upper
row) and to smaller extent also in the sample of T187I (Figure 3,
187C). Fibrils in samples from wild-type mPrP, V209I and V175I
were approximately 7 nm thick. In T187I sample we observed in
addition to the thick fibrils also very thin fibrillar structures
(Figure 3, 187 A,B). The height of these fibrillar structures was
almost ten times lower than of thick fibrils (Figure 3, bottom row
right). It is difficult to precisely determine the height of fibrils using
AFM considering the effects of adsorption or sample drying,
however clearly thinner fibrils in V187I sample probably
correspond to the thinnest fibrillar structures identified previously
[26], which were proposed to consist of a single filament. These
fibrillar structures or filaments have not been observed at the end
stage of fibrillization of wild-type, V175I and V209I mPrPs,
suggesting that T187I substitution either hinders annealing of
filaments into thick fibers or increases the stability of these thin
fibrils, which may lead to their increased number.
T187I forms increased amounts of PrP
res when exposed
to 22L mouse prion strain in cell culture
To address the question if hydrophobic mutations in mouse PrP
would also support PrP
res formation, wild-type mouse PrP and
hydrophobic PrP mutants were also expressed in PrP deficient
hippocampal cell line HpL3–4 [27]. Cells were stably transduced
with pseudotyped retrovirus coding for wild-type and mutant mPrP
and bulk populations of cells were tested for PrP
C expression. PrP
mutants and wild-type mPrP were expressed at comparable levels
on the cell surface as determined by flow cytometry (Table 2). Cell
Enhanced Conversion of Hydrophobic PrP Mutant
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(Figure 4A). After four passages cells were checked for the presence
of proteinase K-resistant prion protein (PrP
res), the marker of prion
infection. Only traces of PrPres were detected in HpL3–4 cell line
stably expressing V209I mutant, from which we concluded that this
mutant poorly supports 22L prion propagation (Figure 4B). On the
contrary, mPrP mutants V175I and V187I allowed efficient 22L
prion propagation as detected by distinctive bands in Western blots
after proteinase K digestion (Figure 4C). Furthermore, the T187I
mutant reproducibly produced more than twice the amount of
PrPres than wild-type mPrP or V175I (Figure 4D, p,0.0001)
suggesting that T187I mutation either increased the susceptibility to
22L prion strain or imposed formation of more proteinase K-
resistant aggregates upon 22L infection.
Discussion
The aim of this study was to investigate the role of hydrophobic
mutations in the H2–H3 subdomain of the globular domain of
PrP. Several hydrophobic mutations in the globular domain are
associated with human prion diseases. Aberrant processing of
several of those mutations (e.g. V180I) was observed in cell culture
experiments [6]. Several mutants also showed decreased thermo-
dynamic stability of PrP
C or increased stability of the folding
intermediate when studied in vitro [5]. Previously we have shown
that separation of subdomain B1-H1-B2 from subdomain H2–H3
is necessary for prion protein conversion while both subdomains
retain the arrangement of their secondary structure elements [11].
Mutation V209I is associated with familial CJD (corresponding to
human PrP amino acid residue 210) and this residue is tightly
embedded in the hydrophobic core and might affect both
subdomain separation as well as their reannealing. On the other
hand, mutations in H2 with increased hydrophobicity, V175I and
T187I, should stabilize subdomain H2–H3, and might thus
facilitate separation of subdomains and conversion. Substitution of
valine for isoleucine at position 209 in mPrP did not affect its
stability, consistent with findings of a previous study [4]. The effect
of this mutation was proposed to lead to increased stability of the
folding intermediate [5]. Molecular dynamics simulations pro-
posed that isoleucine might cause steric crowding in the
hydrophobic core which may cause misfolding [28], however we
observed indistinguishable in vitro conversion. Surprisingly, the
mPrP V209I mutant was inefficiently converted to PrP
res in HpL3-
4 cells exposed to mouse prion strain 22L. Direct prion titer
analysis of different cell populations could not be performed due to
expected transmission barriers introduced by PrP amino acid
substitutions. However, the fact that PrP
res was present in all cell
lines several passages post infection argues that all PrP mutants
were capable of supporting prion infection, albeit likely to different
degrees.
PrP mutation V210I (corresponding to V209I in mouse PrP) is
associated with genetic prion disease in humans, arguing that this
mutation per se is not refractory to prion formation. A likely
explanation is that prion strains differ in their capacities to refold a
given mutant PrP
C into its infectious isoform [29,30]. Further-
more, differences in the human and murine PrP amino acid
sequence context can influence the conversion efficiency of PrP
C,
as has been shown for other PrP mutants [31]. The fact that a
pathogenic PrP amino acid substitution does not generally support
efficient PrP
res formation once again demonstrates different
degrees of compatibility of PrP mutants with different PrP
Sc
conformers [30]. Previously identified mutations which did not
support propagation of 22L prions were mapped to the surface
and were proposed to interfere with packing of PrP
Sc aggregates
[32], whereas V209I lies in the hydrophobic core. Previously
observed differences in the population of the folding intermediate
may be the reason that conversion of this mutant under the
physiological conditions proceeds slowly or towards the nonfi-
brillar aggregates, while in vitro strongly unfolding conditions
decrease this difference.
Two hydrophobic PrP mutants V175I and T187I displayed
increased thermal stability in comparison to the wild-type protein,
indicating that introduced isoleucines interact favorably with H3
and extend the hydrophobic core. Substitution of valine for
isoleucine at position 175 of mPrP did not appreciably alter in vitro
fibrillization kinetics. No overt differences in structure between
wild-type and V175I PrP fibrils were observed by atomic force
microscopy. Furthermore, PrP mutant V175I efficiently supported
PrP
res formation upon 22L prion infection when expressed in
HpL3-4 cells. These results are consistent with the hypothesis that
stabilization of the subdomain H2-H3 by hydrophobic amino acid
substitutions does not interfere with the PrP conversion process.
Interestingly, T187I exhibited an increased lag phase but a
significantly higher amplitude of ThT response compared to wild-
type PrP. We attribute this increased ThT response in T187I
fibrillization at least in part to the formation of very thin fibrils. A
morphological diversity has been previously observed in scrapie-
associated fibrils extracted from prion-infected brains [33,34] and
in vitro prepared fibrils [26]. These thin fibrils of T187I mutant
probably correspond to the previously identified single filament
fibrils, which were very rare in the samples of wild-type mPrP [26].
In accordance with increased in vitro conversion, when cells
expressing T187I were infected with 22L prions, significantly more
PrP
res was produced than in cells expressing wild-type or V175I
mutant. Cell lines expressing the T187I mPrP mutant might
represent good candidates for development of a cell assay with
increased sensitivity. As the increased hydrophobicity at position
187 increases the stability of the globular domain, enhanced
conversion cannot be caused by increased hydrophobic interaction
between PrP monomers. Thr187 is the most exposed to the solvent
of the three investigated mutants. Therefore its replacement by a
more bulky isoleucine residue may prevent efficient lateral packing
of converted filaments into thick fibrils, and maintain a higher
number of nuclei for conversion.
Table 1. Thermal stability of mutant prion proteins.
Protein Tm (6C)
Wild-type 64.760.8
V175I 67.26.1
T187I 68.661.0
V209I 64.661.3
doi:10.1371/journal.pone.0024238.t001
Figure 1. V175, T187 and V209 in murine prion protein can be substituted for isoleucine without large influence on protein
secondary structure. A) Schematic representation of amino-acid residues selected for substitution with more hydrophobic isoleucine. V175 and
T187 reside in H2 and V209 lies in H3. B) CD spectra of wild-type (&), V175I (e), T187I (m), and V209I (,) reveal a high content of a-secondary
structure as expected for mPrP. C) Thermal denaturation curves of wild-type and mutants (symbols used as above).
doi:10.1371/journal.pone.0024238.g001
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by fluorescence intensity of thioflavin T. A representative of four experiments is shown. B) Presence of fibrils was confirmed by TEM. Bar represents
250 nm. C) Final thioflavin T fluorescence intensity of T187I is significantly higher than in the samples of other mPrPs (p,0.0005). The differences
among wild-type, V175I and V209I are not significant.
doi:10.1371/journal.pone.0024238.g002
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Materials
The anti-PrP mouse monoclonal antibody 4H11 has been
described previously [35]. Cy2-conjugated anti-mouse antibodies
were purchased from Dianova, goat anti-mouse HRP conjugated
antibodies from Jackson ImmunoResearch, and Ni-NTA resin was
from Qiagen. TEM grids were from SPI Supplies, mica was from
Ted Pella, GdnHCl and urea were purchased from Fluka, cell
culture media and other chemicals were form Gibco (Invitrogen).
All other chemicals were purchased from Sigma.
Preparation of PrP mutant constructs
For expression in Escherichia coli, single amino acid substitutions
were introduced into the mPrP open reading frame (from residues
23 to 230) cloned into plasmid pRSET A using the Quikchange
kit. Substitutions were also introduced into the mPrP open reading
Figure 3. AFM reveals the presence of thin fibrils in addition to mature fibrils in conversion reactions of T187I. Conversion reactions of
wild-type (WT), V175I, V209I (upper row) and T187I (middle, bottom row) were observed under the atomic force microscope. In all samples fibrils with
approximate height around 7 nm were observed. Cross-section of such fibril from sample T187I is shown (bottom row right, full line). In the T187I
sample in addition to such fibrils, fibrils with less than 1 nm in height were also present (middle row). Image 187B shows a close-up of selected part in
image 187A. Cross-section of thin fibril is shown in the bottom row (bottom row right, broken line). Bar represents 500 nm. Arrows in images 187B
and 187C indicate positions where cross-sections were taken. Images have not been corrected for the width and shape of the AFM tip.
doi:10.1371/journal.pone.0024238.g003
Table 2. Surface expression of mutant prion proteins in prion
protein knockout cell line HpL3–4.
HpL3–4 mPrP % PrP positive cells X-mean
Wild-type 74 41
V175I 67 32
T187I 73 44
V209I 57 42
Flow cytometry analysis confirmed surface expression of mutant and wild-type
mPrP. The number of PrP positive cells as well as the mean fluorescent intensity
of positive cells is given.
doi:10.1371/journal.pone.0024238.t002
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open reading frames were further subcloned into the retroviral
expression vector pSFF using the restriction enzyme sites BamHI
and EcoRI [36,37,38].
Protein expression, purification, and refolding
Plasmid pRSET A encoding mPrP mutants was transformed
into competent E. coli BL21 (DE3) pLysS. Protein expression was
induced by 1 mM IPTG. 4 h after induction cells were harvested
by centrifugation. The protein was purified from inclusion bodies
and refolded on a Ni-NTA-column using a previously described
protocol [39,40,41]. The purity of mutant isolates was checked by
SDS-PAGE.
Circular dichroism spectroscopy
Circular dichroism spectra were recorded on an Applied
Photophysics Chirascan spectropolarimeter. Far-UV CD spectra
were recorded between 190 and 250 nm in a 1 mm path length
cuvette at a protein concentration of 0.1 mg/ml. The thermal
stability of proteins was recorded in a 1 mm path length cuvette at
protein concentrations of 0.1 mg/ml with a temperature scan rate
of 1uC/ min at 222 nm.
A s previously described [42] Tm was obtained from the thermal
transition curves by a fit to the equation:
y~
(yf zmf  T)z(yuzmu  T)  exp
DHM
RT

(T{Tm)
Tm

1zexp
DHM
RT

(T{Tm)
Tm

where y is the observed circular dichroism, ( yf + mf*T ) and ( yu +
mu*T ) describe the linear dependence of the pretranslational
and posttransitional baselines on temperature, DHm is the
enthalpy change for unfolding at Tm, and Tm is the midpoint of
the thermal unfolding curve. Two-state model equation described
above was implemented into the program Origin 8.1 (MicroCal,
GE Healthcare).
In vitro conversion of the prion protein
A conversion reaction adopted from Bocharova et al. [43] was
used for tracking the fibrillization of PrP mutants. Correctly folded
proteins were first denatured in 6 M GdnHCl and further diluted
into 1 M GdnHCl, 3 M urea, phosphate buffered saline pH 6.8 at
protein concentrations of 22 mM. Amyloid specific dye Thioflavin
T( 5mM) was added and the samples were loaded into micro-
titer wells each containing 3 teflon balls [43]. Microtiter plate
was shaked at 1000 rpm at 37uC and thioflavin T fluorescence
Figure 4. Cell line HpL3-4 expressing T187I produces more PrP
res than cell lines expressing wild-type and other mutants when
infected by mouse prion strain 22L. A) Stably transduced HpL3–4 bulk populations expressing wild-type and mutant PrP proteins were exposed
to mouse-adapted prion strain 22L and subsequently passaged in the absence of inoculum for 4 passages. B) Cell lysates of HpL3–4 cell populations
expressing wild-type mPrP or mPrP V209I were tested for PrP
res content. While mutant V209I expressed well in HpL3–4 (non-digested by proteinase K,
-PK), only weak bands of PrP
res are present in this cell population (+PK). C) Wild-type mPrP, mPrP V175I and mPrP T187I-expressing HpL3–4s were
infected by 22L prions (5 parallels each). Upper part shows PrP
res (+PK), middle part non-digested cell lysate (-PK) and bottom line GAPDH loading
control. D) Analysis of averaged normalized intensity of PrP
res reveals significantly higher amount of PrP
res present in cell lysates of HpL3–4s
expressing T187I (p,0.0001).
doi:10.1371/journal.pone.0024238.g004
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Microplate Reader (Berthold Technologies) equipped with
440 nm excitation filter. Statistical analysis was performed in
Graphpad Prism using one-way nonparametric ANOVA test.
Analysis of fibril formation
Transmission electron microscopy was carried out as previously
described [40]. To observe conversion reaction by atomic force
microscopy a drop of fibrillization mixture (diluted to 0.22 mM)
was applied to freshly cleaved mica (Ted Pella) and left to adsorb
for 5 min after which it was washed twice with filtered Milli-Q
water and dried under nitrogen. Samples were observed by Agilent
Technologies 5500 Scanning Probe Microscope operating in
acoustic alternating current mode utilizing silicon cantilevers
(Arrow-NCR, NanoWorld) as previously described [11].
Production of retrovirions and transduction of HpL3-4
The pSFF vector and the packaging plasmids pVPack-GP and
pVPack-VSV-G (Stratagene, La Jolla, CA, USA) were transfected
into HEK293-FT (Invitrogen) cells using Lipofectamine 2000
according to the manufacturer’s recommendations. Retroviral
supernatants were harvested 48 h post transfection and cleared of
cell debris by filtration through a 0.45 mm filter. Retroviral
supernatants were diluted in growth medium and mixed with
DEAE-Dextran or polybrene to a final concentration of 10 mg/ml
or 4 mg/ml, respectively. HpL3-4 cells were incubated with
retroviral particles for 3 h at 37uC. After addition of 2 ml growth
medium cells were incubated for additional 24 h. Cells were then
rinsed, expanded and subsequently tested for PrPC expression.
Flow cytometry
We used a flow cytometry protocol adapted from Maas et al. to
check whether PrP hydrophobic mutants are expressed at the cell
surface of HpL3-4 cells similarly to the wild-type PrP [32]. 5610
5
cells were first incubated with FACS buffer (2.5 % FCS in PBS) for
10 min at 4uC. 100 ml of 4H11 antibody was added to the cells
and incubated for 45 min at 4uC. After washing, the cells were
incubated with Cy2-conjugated anti-mouse secondary antibodies
for 45 min at 4uC in the dark. The rinsed cells were analyzed by
flow cytometry.
Infection of HpL3-4
A day before infection 5610
4 cells were seeded into each well of
a 24-well microtiter plate. 200 mL of DMEM supplemented with
10% serum and 1% 22L-positive brain homogenate were added to
the cells and incubated for 4 h. After this incubation 400 mLo f
growth medium were added and the cells were left to grow to near
confluence when the cells were subsequently expanded into 6 cm
and 9 cm Petri dishes [32,44].
Analysis of protease-resistant PrP
Infected HpL3-4 cells were rinsed in PBS and lysed in cold lysis
buffer (10 mM Tris–HCl pH 7.5, 100 mM NaCl, 10 mM EDTA,
0.5% Triton X-100, 0.5% DOC). Cell lysates were cleared of cell
debris (20 000x g, 1 min). 1/10 of the sample was precipitated in
four volumes of methanol and used for determination of the total
amount of PrP. The remaining sample was incubated with
proteinase K (20 mg/ml) at 37uC for 60 min. Proteolysis was
terminated by addition of Pefabloc and lysates were centrifuged at
356.000xg for 1 h at 4uC. Pellets were resuspended in SDS-sample
buffer (2.5% SDS, 3 mM EDTA, 2% b-mercaptoethanol, 5%
glycerol, 0.02% bromphenol blue and 63 mM Tris-HCl pH 6.8
and analyzed by Western blot. PrP was detected by the mouse
monoclonal antibody 4H11 and enhanced chemiluminescence
according to the manufacturer’s recommendations (ECL Plus,
Amersham Biosciences). Bands corresponding to PrP
res were
analyzed by densitometry and normalized to control GAPDH. As
in the case of in vitro conversion statistical analysis was performed
with Graphpad Prism using one-way nonparametric ANOVA.
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